ATE477495T1 - Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor - Google Patents

Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor

Info

Publication number
ATE477495T1
ATE477495T1 AT06738465T AT06738465T ATE477495T1 AT E477495 T1 ATE477495 T1 AT E477495T1 AT 06738465 T AT06738465 T AT 06738465T AT 06738465 T AT06738465 T AT 06738465T AT E477495 T1 ATE477495 T1 AT E477495T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
egfr kinase
methods
inhibition
emt
Prior art date
Application number
AT06738465T
Other languages
English (en)
Inventor
John Haley
Graeme Griffin
Lukas Amler
David Eberhard
Robert Yauch
Original Assignee
Osi Pharm Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc, Genentech Inc filed Critical Osi Pharm Inc
Application granted granted Critical
Publication of ATE477495T1 publication Critical patent/ATE477495T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT06738465T 2005-03-16 2006-03-16 Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor ATE477495T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66254505P 2005-03-16 2005-03-16
US67182105P 2005-04-15 2005-04-15
PCT/US2006/009403 WO2006101925A2 (en) 2005-03-16 2006-03-16 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE477495T1 true ATE477495T1 (de) 2010-08-15

Family

ID=36586095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06738465T ATE477495T1 (de) 2005-03-16 2006-03-16 Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor

Country Status (7)

Country Link
US (3) US8093011B2 (de)
EP (1) EP1861715B1 (de)
JP (1) JP5085529B2 (de)
AT (1) ATE477495T1 (de)
CA (1) CA2601157A1 (de)
DE (1) DE602006016085D1 (de)
WO (1) WO2006101925A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070020A2 (en) * 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CA2623125A1 (en) * 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN101677977A (zh) * 2006-11-10 2010-03-24 欣达克斯制药公司 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合
KR100934706B1 (ko) * 2006-12-07 2009-12-31 재단법인서울대학교산학협력재단 Ｔｍ４ｓｆ５의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
JP5240739B2 (ja) * 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
EP2179291B1 (de) * 2007-07-13 2014-10-22 Nestec S.A. Arzneistoffauswahl für die lungenkrebstherapie unter verwendung von arrays auf antikörperbasis
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
EP2522754B1 (de) * 2007-08-13 2014-04-02 Baxter International Inc. IVIg-Modulation von Chemokinen zur Behandlung von Multipler Sklerose, Morbus Alzheimer und Morbus Parkinson
BRPI0815415A2 (pt) 2007-08-14 2015-02-03 Hoffmann La Roche Marcador preditivo para tratamento inibidor de egfr
WO2009021673A1 (en) 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive markers for egfr inhibitors treatment
CA2695070A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
MX2010001579A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Maracador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
EP2036576A1 (de) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B-Fibronektin als Stratifizierungsmarker für Antitumormittel
JP2010540960A (ja) * 2007-10-03 2010-12-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
WO2009045389A2 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2207892A4 (de) 2007-10-15 2010-12-08 Precision Therapeutics Inc Verfahren zur selektion aktiver agentien für die krebsbehandlung
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
EP2071336A1 (de) * 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serumproteom zum Finden von diagnostischen Markern und zur Überwachung des therapeutischen Eingriffs bei der Behandlung von Leberzellenkarzinom
KR20100135780A (ko) * 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
US7998688B2 (en) * 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
EP2271941B1 (de) * 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Verfahren zur identifizierung von mesenchymähnliche tumorzellen oder deren bildung hemmenden stoffen
EP2274617A4 (de) * 2008-04-10 2011-11-09 Massachusetts Inst Technology Verfahren zur erkennung und verwendung von auf krebsstammzellen abzielenden mitteln
EP2281027A4 (de) * 2008-05-14 2011-07-27 Precision Therapeutics Inc Verfahren zur vorhersage der reaktion eines patienten auf egfr-hemmer
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
JP2012519170A (ja) * 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120095030A1 (en) * 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
EP2419177A1 (de) * 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Biologische marker zur vorhersage einer anti-krebs-antwort auf epidermale wachstumsfaktor-rezeptor-kinase-inhibitoren
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120095029A1 (en) * 2010-10-15 2012-04-19 Hoffmann-La Roche Inc. Ipp complex as marker for erlotinib treatment
US20140155397A1 (en) * 2011-04-01 2014-06-05 Board Of Regents Emt signatures and predictive markers and method of using the same
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US10260097B2 (en) * 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
EP2751285B2 (de) 2011-08-31 2020-04-01 Genentech, Inc. Methode zur bestimmung der empfindlichkeit eines tumors für egfr kinase-inhibitoren
EP2761025A1 (de) 2011-09-30 2014-08-06 Genentech, Inc. Diagnostische methylierungsmarker vom epithelialen oder mesenchymalen phenotyp und reaktion auf egfr-kinaseinhibitor bei tumoren oder tumorzellen
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
ES2797533T3 (es) 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
WO2013146993A1 (ja) * 2012-03-28 2013-10-03 株式会社オンチップ・バイオテクノロジーズ 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
EP2895623B1 (de) 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Verwendung von e-cadherin und vimentin zur auswahl von auf eine behandlung ansprechenden patienten
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
MX369691B (es) 2012-11-21 2019-11-19 Agios Pharmaceuticals Inc Inhibidores de glutaminasa y métodos de empleo.
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
SG11201504023SA (en) 2012-12-03 2015-06-29 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US9782075B2 (en) 2013-03-15 2017-10-10 I2Dx, Inc. Electronic delivery of information in personalized medicine
US11089959B2 (en) 2013-03-15 2021-08-17 I2Dx, Inc. Electronic delivery of information in personalized medicine
US9851358B2 (en) * 2014-01-08 2017-12-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination
BR112016021620A2 (pt) 2014-03-21 2018-07-10 Agios Pharmaceuticals Inc compostos e seus métodos de uso
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US10539566B2 (en) 2014-12-08 2020-01-21 Berg Llc Use of markers including filamin A in the diagnosis and treatment of prostate cancer
WO2017104821A1 (ja) 2015-12-18 2017-06-22 日本ゼオン株式会社 浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用
JP6789512B2 (ja) * 2016-05-10 2020-11-25 学校法人日本医科大学 肺癌治療のための抗癌剤の効果の検査法
WO2019178167A1 (en) * 2018-03-13 2019-09-19 I2Dx, Inc. Electronic delivery of information in personalized medicine
CN113312056B (zh) * 2021-06-16 2022-04-19 浪潮云信息技术股份公司 angular大型集成项目的国际化实现方法、电子设备及存储介质

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US5925519A (en) * 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
JP2002511852A (ja) 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
EP1028964A1 (de) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidin- und thienopyridin-derivate als antikrebsmittel
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
ES2161612B1 (es) 1999-07-01 2002-06-01 Consejo Superior Investigacion Procedimiento para identificar un compuesto que inhiba la funcion represora de snail.
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
AU2003209340A1 (en) 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
EP1510221A4 (de) * 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp Mittel zur prävention und/oder behandlung für personen mit expression oder aktivierung von her2 und/oder egfr
DE60310922T2 (de) 2002-06-05 2007-10-11 Cedars-Sinai Medical Center, Los Angeles Gefitinib (iressa) zur behandlung von krebs
AU2003251597A1 (en) 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
CA2512536A1 (en) 2003-01-08 2004-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2004065602A1 (es) 2003-01-17 2004-08-05 Universidad Autónoma de Madrid Procedimiento para identificar la transición epitelio-mesenquimal de células mesoteliales (temcm) e identificar compuestos moduladores de temcm, composiciones farmacéuticas y su uso en el diagnóstico y tratamiento de enfermedades que cursan con temcm
AU2004211955B2 (en) 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
JP3762975B2 (ja) * 2003-03-18 2006-04-05 学校法人慶應義塾 単球由来多能性細胞ｍｏｍｃ
AU2004248140A1 (en) 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP1664716A4 (de) 2003-08-15 2008-08-13 Smithkline Beecham Corp Krebs-biomarker
JP2007537717A (ja) 2004-01-07 2007-12-27 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
WO2005094332A2 (en) 2004-03-26 2005-10-13 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2005107803A2 (en) 2004-05-06 2005-11-17 Vernalis Plc Methods of determining the prognosis and treatment of subjects with lung cancer
ES2537631T3 (es) 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
KR20080003334A (ko) 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2007028146A2 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2009520028A (ja) 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
JP5240739B2 (ja) 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
AU2008221604B2 (en) 2008-09-22 2010-04-22 Commonwealth Scientific And Industrial Research Organisation Temperature-responsive polymer particles in protein separation applications
EP2419177A1 (de) 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Biologische marker zur vorhersage einer anti-krebs-antwort auf epidermale wachstumsfaktor-rezeptor-kinase-inhibitoren

Also Published As

Publication number Publication date
EP1861715A2 (de) 2007-12-05
CA2601157A1 (en) 2006-09-28
US20160158235A1 (en) 2016-06-09
JP2008533490A (ja) 2008-08-21
US9244058B2 (en) 2016-01-26
WO2006101925A2 (en) 2006-09-28
US20060211060A1 (en) 2006-09-21
WO2006101925A3 (en) 2007-02-01
DE602006016085D1 (de) 2010-09-23
US20120157480A1 (en) 2012-06-21
EP1861715B1 (de) 2010-08-11
JP5085529B2 (ja) 2012-11-28
US8093011B2 (en) 2012-01-10

Similar Documents

Publication Publication Date Title
ATE477495T1 (de) Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
ATE533057T1 (de) Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
WO2008127718A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2009045389A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045361A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
Nie et al. Long non‐coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival
Rossé et al. Control of MT1-MMP transport by atypical PKC during breast-cancer progression
Gazzaniga et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis
Rodrigo et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas
DE602005019294D1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Adler et al. Metastatic pathways in patients with cutaneous melanoma
Wang et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder
Grupp et al. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence
Bidard et al. Translating metastasis-related biomarkers to the clinic—progress and pitfalls
Santos et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder
Wagner et al. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Luo et al. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma
Gioacchini et al. The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma
Torrisi et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
Zhang et al. Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma
Grupp et al. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy
Nie et al. Prognostic significance of long noncoding RNA Z38 as a candidate biomarker in breast cancer
MX2022005159A (es) Uso de biomarcadores para predecir la sensibilidad clinica a 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida.
Cao et al. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma
Dai et al. Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties